EyePoint signs lease for 40,000 sq ft manufacturing facility; rent starts H2 2024

EyePoint, Inc.

Lease for build-to-suit cGMP facility in Northbridge, MA to support EYP-1901 and YUTIQ manufacturing.
Annual base rent ~$2.44M ($61/sq ft), escalating to ~$3M over 15-year initial term; total ~$41M.
Rent commences in H2 2024 after construction; facility expected operational in H2 2024.
Awarded $1.9M in state and local tax incentives as part of the agreement.
Two renewal options (5 or 10 years) at 95% of fair market rent; expansion right up to 20,000 sq ft.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

EyePoint, Inc. entered into Lease with V.E. Properties IX, LLC valued at approximately $41 million (effective 2023-01-23).

Action: entry
Agreement: lease
Counterparty: V.E. Properties IX, LLC
Value: approximately $41 million
Effective: 2023-01-23

Exact text from the filing

On January 23, 2023, EyePoint Pharmaceuticals, Inc. (the “Company”) and V.E. Properties IX, LLC (the “Landlord”) entered into a lease agreement (the “Lease”) relating to the lease by the Company of a to-be-constructed build-to-suit stand-alone commercial manufacturing facility

View on SEC.gov

Browse all material agreements →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.